• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亨廷顿舞蹈症中的蛋白质聚集。

Protein aggregation in Huntington's disease.

作者信息

Hoffner Guylaine, Djian Philippe

机构信息

UPR 2228-CNRS, Institut Interdisciplinaire des Sciences du Vivant des Saints-Pères, Université René-Descartes, 45, rue des Saints-Pères, 75270 cedex 6, Paris, France.

出版信息

Biochimie. 2002 Apr;84(4):273-8. doi: 10.1016/s0300-9084(02)01398-6.

DOI:10.1016/s0300-9084(02)01398-6
PMID:12106904
Abstract

The presence of an expanded polyglutamine produces a toxic gain of function in huntingtin. Protein aggregation resulting from this gain of function is likely to be the cause of neuronal death. Two main mechanisms of aggregation have been proposed: hydrogen bonding by polar-zipper formation and covalent bonding by transglutaminase-catalyzed cross-linking. In cell culture models of Huntington's disease, aggregates are mostly stabilized by hydrogen bonds, but covalent bonds are also likely to occur. Nothing is known about the nature of the bonds that stabilize the aggregates in the brain of patients with Huntington's disease. It seems that the nature of the bond stabilizing the aggregates is one of the most important questions, as the answer would condition the therapeutic approach to Huntington's disease.

摘要

多聚谷氨酰胺的扩增会在亨廷顿蛋白中产生毒性功能获得。这种功能获得导致的蛋白质聚集很可能是神经元死亡的原因。已经提出了两种主要的聚集机制:通过极性拉链形成的氢键和转谷氨酰胺酶催化的交联形成的共价键。在亨廷顿病的细胞培养模型中,聚集体大多通过氢键稳定,但共价键也可能会出现。对于稳定亨廷顿病患者大脑中聚集体的化学键性质尚无了解。稳定聚集体的化学键性质似乎是最重要的问题之一,因为答案将决定亨廷顿病的治疗方法。

相似文献

1
Protein aggregation in Huntington's disease.亨廷顿舞蹈症中的蛋白质聚集。
Biochimie. 2002 Apr;84(4):273-8. doi: 10.1016/s0300-9084(02)01398-6.
2
Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers.亨廷顿舞蹈病患者神经元内含物的纯化揭示了一系列广泛的扩展型亨廷顿蛋白N端片段和不溶性聚合物。
J Neurochem. 2005 Oct;95(1):125-36. doi: 10.1111/j.1471-4159.2005.03348.x.
3
Huntingtin fragments that aggregate go their separate ways.聚集的亨廷顿蛋白片段各自分离。
Mol Cell. 2002 Aug;10(2):224-5. doi: 10.1016/s1097-2765(02)00609-3.
4
A cellular model that recapitulates major pathogenic steps of Huntington's disease.一种概括亨廷顿舞蹈症主要致病步骤的细胞模型。
Hum Mol Genet. 1998 Sep;7(9):1355-61. doi: 10.1093/hmg/7.9.1355.
5
In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.关于细胞核和细胞质作为亨廷顿病发病机制亚细胞位点的体外证据。
Hum Mol Genet. 1999 Jan;8(1):25-33. doi: 10.1093/hmg/8.1.25.
6
Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.谷氨酰胺重复序列扩增的亨廷顿蛋白截短型N端片段在细胞培养中形成核内和胞质聚集体。
Hum Mol Genet. 1998 May;7(5):783-90. doi: 10.1093/hmg/7.5.783.
7
Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.亨廷顿病果蝇模型中亨廷顿蛋白聚集的动力学及其病理作用。
Genetics. 2012 Feb;190(2):581-600. doi: 10.1534/genetics.111.133710. Epub 2011 Nov 17.
8
14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.14-3-3ζ蛋白对于多聚谷氨酰胺扩展的亨廷顿蛋白的聚集体形成是不可或缺的。
Neurosci Lett. 2008 Jan 24;431(1):45-50. doi: 10.1016/j.neulet.2007.11.018. Epub 2007 Nov 17.
9
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.包涵体的形成降低了突变亨廷顿蛋白的水平以及神经元死亡的风险。
Nature. 2004 Oct 14;431(7010):805-10. doi: 10.1038/nature02998.
10
Are there multiple pathways in the pathogenesis of Huntington's disease?亨廷顿舞蹈症的发病机制中是否存在多种途径?
Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):995-1003. doi: 10.1098/rstb.1999.0451.

引用本文的文献

1
Quantification of Protein Secondary Structures from Discrete Frequency Infrared Images Using Machine Learning.利用机器学习从离散频率红外图像中定量分析蛋白质二级结构
Appl Spectrosc. 2025 Mar 31:37028251325553. doi: 10.1177/00037028251325553.
2
Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease.探讨亨廷顿病的分子机制、治疗策略和临床表现。
Arch Pharm Res. 2024 Jun;47(6):571-595. doi: 10.1007/s12272-024-01499-w. Epub 2024 May 19.
3
Big versus small: The impact of aggregate size in disease.
大与小:聚集大小对疾病的影响。
Protein Sci. 2023 Jul;32(7):e4686. doi: 10.1002/pro.4686.
4
Current and Possible Future Therapeutic Options for Huntington's Disease.亨廷顿舞蹈症当前及未来可能的治疗选择
J Cent Nerv Syst Dis. 2022 May 21;14:11795735221092517. doi: 10.1177/11795735221092517. eCollection 2022.
5
Cellular stress responses in protein misfolding diseases.蛋白质错误折叠疾病中的细胞应激反应。
Future Sci OA. 2015 Sep 1;1(2):FSO42. doi: 10.4155/fso.15.42. eCollection 2015 Sep.
6
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.靶向胆碱能系统开发亨廷顿舞蹈病的新型疗法
J Huntingtons Dis. 2016 Dec 15;5(4):333-342. doi: 10.3233/JHD-160200.
7
Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.在小鼠N171-82Q亨廷顿病模型中,阿米替林通过增强神经营养因子信号传导和线粒体功能来改善运动功能。
J Biol Chem. 2015 Jan 30;290(5):2728-43. doi: 10.1074/jbc.M114.588608. Epub 2014 Dec 11.
8
Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?亨廷顿舞蹈症中的聚谷氨酰胺聚集:结构决定毒性吗?
Mol Neurobiol. 2015 Dec;52(3):1297-1314. doi: 10.1007/s12035-014-8932-1. Epub 2014 Oct 22.
9
Metabolic states following accumulation of intracellular aggregates: implications for neurodegenerative diseases.细胞内聚集物积累后的代谢状态:对神经退行性疾病的影响。
PLoS One. 2013 May 7;8(5):e63822. doi: 10.1371/journal.pone.0063822. Print 2013.
10
Huntington's disease: can mice lead the way to treatment?亨廷顿病:老鼠能为治疗指明方向吗?
Neuron. 2011 Feb 10;69(3):423-35. doi: 10.1016/j.neuron.2010.12.035.